Business Wire

MA-TRANSMIT-SECURITY

12.5.2022 07:32:09 CEST | Business Wire | Press release

Share
Transmit Security Expands in Europe

Transmit Security , a leading provider of customer identity and access management (CIAM) SaaS solutions, today announced its significant expansion and growth in Europe to address rapidly growing demand for passwordless customer authentication and other solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511006152/en/

In January, the company hired Dr. Thore Rabe as the new Vice President and General Manager for Europe, Middle East and Africa (EMEA). Rabe oversees all aspects of Transmit Security’s business in EMEA. Thore has over 20 years leading European divisions at Qumulo, Dell EMC, NetApp, Fujitsu Siemens, and Computer Associates and earned his doctorate in Economic Sciences.

“Our expansion comes at a critical time, not just for us, but for the market here in Europe. With the increase in account takeover fraud , we’re seeing substantial demand for passwordless customer authentication that doesn’t require a specialized app or token,” says Rabe. “The pandemic-fuelled growth in mobile app usage along with the brick-and-mortar return of consumers means businesses need stronger, easy-to-use authentication that works across all of their channels. Our customers know they have to serve their consumers digitally, no matter where they are or what devices they use.”

Consumers around the world report that they prefer better security and smooth customer experience ; businesses are increasingly turning to passwordless authentication as the solution. With the growing demand in Europe, Transmit Security has invested heavily in the region, more than doubling its Europe-based employees and growing by 255% across EMEA, including its corporate headquarters in Tel Aviv.

Transmit Security’s customers in EMEA include HSBC, UBS, Telepass S.p.A., Santander, MetroBank and NN Insurance, and dozens of other regional and global companies. Transmit Security helps its customers in the region address many customer identity challenges, including improving customer experience across their digital channels while strengthening authentication against phishing and other threats. Altogether, the company’s customers in EMEA represent over €330 billion in annual revenues.

Transmit Security is a Platinum Sponsor at the Gartner Identity & Access Management Summit on May 12-13 in London (booth 202). They will be presenting, “Fortify Security and Remove Customer Barriers with Passwordless” on Friday at 2:45pm.

About Transmit Security

Transmit Security is on a mission to revolutionize consumer identity and access management by reimagining customer experience (CX) and eliminating account takeover fraud and similar risks. CX-focused, cybersecurity-conscious businesses rely on Transmit Security to deliver innovative, passwordless digital identity journeys for their consumers across all channels and devices. Transmit Security’s customers are responsible for more than $1.3 trillion in annual commerce and include many of the largest banks, insurers, and retailers, along with many other leading brands.

For more information, please visit www.transmitsecurity.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye